+39 02 610346.1 - info@newron.com

Press Releases

Filter by year
  • october62017

    Newron Pharmaceuticals Supports Rett Syndrome Awareness Month this October

  • september262017

    Newron raises CHF 27.0 Million in a private placement of new shares.

     

  • september262017

    Newron raises CHF 27.0 Million in a private placement of new shares

     

  • september252017

    Newron launches a private placement of new shares

     

  • september252017

    Newron launches a private placement of new shares.

     

  • september142017

    Newron reports half-year 2017 results

     

  • july112017

    XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE PATIENTS

     

  • may172017

    Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age

     

  • may122017

    Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago® (safinamide)

     

  • april112017

    Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada

  • april102017

    ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease

     

  • april52017

    Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia

  • march282017

    Newron Shareholders Confirm Company Management

     

  • march252017

    Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia

     

  • march212017

    FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS

     

  • march162017

    Newron to Present at the 16th International Congress on Schizophrenia Research

     

  • march22017

    Newron announces 2016 financial results and provides outlook for 2017 Board approves agenda for AGM on March 28, 2017

     

  • february212017

    Newron Supports Global Rare Disease Day® 2017 and Rett Syndrome Studies

     

  • january102017

    Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand

  • january32017

    Evenamide met study objectives of good tolerability, safety, and preliminary evidence of efficacy as an add-on therapy for the treatment of schizophrenia- unique MoA